Smartphone App for Smoking Cessation

Overseen by Jennifer A. Minnix

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial studies how well two smartphone apps, KickAsh and Breathe2Relax, help smokers with depressive symptoms quit smoking. KickAsh teaches relaxation skills, and Breathe2Relax improves mood and encourages fun activities. KickAsh combines methods from various approaches to help smokers quit.

Research Team

Jennifer A. Minnix

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for English-speaking MD Anderson patients aged 18-65 who smoke daily, own an iOS device with regular app usage, and are willing to set a quit date within 30 days. They must have smoked for at least a year and either currently have or previously had depressive symptoms. People can't join if they're in another smoking cessation program or have health issues that make the study unsafe for them.

Inclusion Criteria

I am a patient at MD Anderson, aged between 18 and 65.

I am willing to commit to quitting smoking within the next 30 days.

Not engaged in smoking cessation treatment other than the MDACC Tobacco Treatment Program

Exclusion Criteria

I don't have any health or mental conditions that could make the treatment unsafe for me.

Subject considered by the investigator an unsuitable candidate for receipt of a smoking cessation treatment or unstable to be followed up throughout the entire duration of the study

Treatment Details

Interventions

• Smartphone Mobile Application (Behavioural Intervention)

Trial Overview The study is testing how effective smartphone apps are in helping smokers quit. Participants will use these apps as part of their smoking cessation treatment to see if it enhances their ability to stop smoking.

Participant Groups

Group I: Group II (Breathe2Relax smartphone mobile application) Experimental Treatment 2 Interventions

Participants receive Breathe2Relax smartphone mobile application designed to help improve mood and increase level of enjoyable activities over 8 weeks.

Group II: Group I (KickAsh smartphone mobile application) Experimental Treatment 2 Interventions

Participants receive KickAsh smartphone mobile application designed to help the learning of relaxation skills over 8 weeks.

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

Dr. Peter WT Pisters

M.D. Anderson Cancer Center

Chief Executive Officer since 2017

MD from University of Western Ontario

Dr. Jeffrey E. Lee

M.D. Anderson Cancer Center

Chief Medical Officer

MD from Stanford University School of Medicine

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School